Enhanced pharmacological activity of recombinant human interleukin-11 (rhIL11) by chemical modification with polyethylene glycol.

In order to improve the pharmacological efficacy of recombinant human interleukin-11 (rhIL11) and to reduce the frequency of administration, we examined the feasibility of chemical modification of rhIL11 by polyethylene glycol. The rhIL11 was chemically modified by using branched type (PEG2), or linear type (PEG) polyethylene glycol-N-hydroxysuccinimide with various molecular weights. Plasma profiles of immunoreactive rhIL11 after i.

Incorporation into a biodegradable hyaluronic acid matrix enhances in vivo efficacy of recombinant human interleukin 11 (rhIL11).

In order to improve the therapeutic efficacy of recombinant human interleukin 11 (rhIL11) and to reduce its frequency of administration, the feasibility of a sustained release formulation consisting of hyaluronic acid (HyA) was investigated. rhIL11 was mixed together with an aqueous solution of HyA or HyA and protamine, and the mixture was lyophilized. The resulting powder was compressed into pellet and was subcutaneously administered in the rats.